The Global Innovation and Development team of Phillips-Medisize, a Molex company, considers the approach to developing a novel drug delivery device for age-related macular degeneration. Read the article published in ONdrugDelivery to learn how to work through ideation, assess user needs, investigate feasibility and more to approach drug delivery approaches for the eye.


March 2022 | Issue No 130 | Page 50-52

Read the Article

View Product Pages, Blogs, and Other Resources

Phillips-Medisize Smart Autoinjector - Reducing Waste Product Shot

A breakthrough in autoinjector innovation, the small, easy-to-use Aria combines reusable and disposable components along with full connectivity and digital patient guidance to improve patient care and comfort. Offering customizable, differentiated performance while reducing environmental impact, Aria brings new potential in the drug delivery market.

Bring Your Drug Delivery Device to Life
Learn More

Advanced Medical Innovation, Design and Production

The future is rich with potential for medical technology — and a better, connected patient experience is at the center of it. Improving lives by bringing more advanced care closer to home is not only possible but emerging rapidly.

For decades, Phillips-Medisize, a Molex company, has been laser focused on contract design and manufacturing of products in highly regulated industries such as Pharmaceuticals, where precision, reliability and quality are critical.

Read What Experts Are Saying
Go to Blog

Exact Sciences and Phillips-Medisize Collaborate to Fight Colorectal Cancer

Exact Sciences, a leader in cancer testing, developed a game-changing at-home colorectal cancer kit, but needed support to build the highest quality product. With decades of manufacturing innovation for healthcare and life sciences companies, Exact Sciences found a quality-first collaborator in Phillips-Medisize.

Blend Innovative Science and Advanced Manufacturing
Read Case Study

This article is taken from ONdrugDelivery Ophthalmic Drug Delivery Issue No 130 March 2022, pages 50-52.

© 2021 Frederick Furness Publishing Ltd